Contract signed with second leading CRO
Trellus Health plc (AIM: TRLS) announced a 12-month contract with a second major global clinical research organisation to deploy its Trellus TrialSet™ offering, commencing before year-end. This agreement, structured with an upfront fee, monthly management fee, and milestone payments, will support recruitment and enrolment optimisation for two late-stage immunology and inflammation clinical trials. While this marks a strategic growth area and validates their offering, the company explicitly stated the contract does not immediately extend its cash runway beyond early December 2025. Trellus Health continues to explore options for a potential equity fundraising, a critical factor for investors given the short cash runway.
Select text to share a quote on X · sign in to keep highlights & notes in your TRLS notes
LONDON, U.K. AND NEW YORK, U.S. (07 November 2025). Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces it has signed a 12 month contract (the "Contract") with one of the largest global clinical research organisations ('CRO's') to utilise its Trellus TrialSet™ offering. The Contract is due to commence before year end, and will focus on immunology and inflammation, supporting recruitment and enrolment optimisation for two late-stage clinical trials.
This marks the Company's second contract with a leading CRO, further reinforcing the clinical trials sector as a strategic growth area for Trellus Health®. The Trellus TrialSet™ program is designed to enhance clinical trial recruitment by identifying individuals with lower resilience who may be hesitant to enrol and providing structured, evidence-based support to strengthen their resilience and readiness for participation.
The Contract, which includes an upfront fee, a monthly management fee, and milestone payments, is structured around three key performance indicators: (i) the number of potential eligible participants opting into the Trellus TrialSet™ program, (ii) the increase in qualified participants referred for screening, and (iii) the reduction in the screen failure rate.
Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "This represents another important milestone for Trellus Health®, underscoring the intrinsic value of our Trellus TrialSet™ digital solution and reflecting our continued focus on strategic execution. Since its launch earlier this summer, we have entered into two agreements with leading CROs, validating the relevance and differentiation of our offering. While the contract does not immediately extend the Company's current cash runway beyond early December 2025, combined with the Patient Support Program agreement signed with Johnson & Johnson in January 2025 which launched in the spring, these milestones demonstrate the growing recognition of the value Trellus Health delivers to the pharmaceutical sector.
"The Company continues to explore options for a potential equity fundraising and further updates will be provided in due course, as appropriate."
Regulatory Information
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.